Orthoplastics is one of the major UHMWPE suppliers to the strictly regulated orthopedic implant market. With its rigorous quality-compliance system, Orthoplastics not only supplies UHMWPE material, but also produces implantable orthopedic components to customer specifications. Orthoplastics gains production capacity for components, while MedPlast is able to expand its footprint in Europe for medical applications.
“Through this acquisition, MedPlast can accelerate its growth into the medical device assembly and implantables markets,” said Harold Faig, CEO of MedPlast. “The combination of MedPlast and Orthoplastics represents tremendous opportunities for both firms and for our customers.”
Matt Langton, Executive VP of sales and marketing for MedPlast, added, “Orthoplastics becomes a key part of our strategy to deliver comprehensive processing technologies to the global medical device market. This will provide our current and future customers with a wider range of capabilities that become even more valuable as the design of medical products grows increasingly sophisticated and regulated.”
Managing Director of Orthoplastics, David Brooks, commenting on the acquisition by MedPlast, saying, “This acquisition allows MedPlast to combine its technical capabilities with Orthoplastics’ implantable technologies to become a significant player in the implantable market.”
MedPlast, headquartered in Tempe, AZ, brings expertise in a variety of plastics processes including injection molding, blowmolding, silicone extrusion, compression and transfer molding, liquid injection molding (LIM), two-shot molding, overmolding, insert molding, and multi-component molding. MedPlast also provides precision mold manufacturing.
Orthoplastics has developed technology to produce premium-grade UHMWPE material to the highest quality standards, as well as patenting a method of gamma crosslinking in bulk with close dosage control – important to orthopedic device customers. Orthoplastics’ capabilities include direct compression molding (DCM), ram extrusion, annealing, machining and finishing, inspection and laboratory testing.
“Driven by an increasingly aging population and healthcare legislation, MedPlast’s robust product line addresses the need for effective orthopedic solutions in both developed and developing countries,” Faig stated.
In addition to its Tempe headquarters manufacturing site, MedPlast has facilities in Chicopee, MA; Elkhorn, WI; Fremont, CA; West Berlin, NJ; Westfield, PA; and Monticello IA. The company also has operations in Suzhou, China and Tijuana, Mexico. MedPlast has played a key role in the introduction of many new, and highly challenging, production introductions in the healthcare marketplace.
